LeMaitre Vascular ROA 2007-2018 | LMAT
Current and historical return on assets (ROA) values for LeMaitre Vascular (LMAT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. LeMaitre Vascular ROA for the three months ending September 30, 2018 was 15.38%.
| LeMaitre Vascular ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-09-30 | $0.02B | $0.14B | 15.67% |
| 2018-06-30 | $0.02B | $0.14B | 17.15% |
| 2018-03-31 | $0.02B | $0.13B | 14.75% |
| 2017-12-31 | $0.02B | $0.13B | 14.59% |
| 2017-09-30 | $0.02B | $0.12B | 14.48% |
| 2017-06-30 | $0.01B | $0.11B | 13.27% |
| 2017-03-31 | $0.01B | $0.11B | 11.82% |
| 2016-12-31 | $0.01B | $0.10B | 11.22% |
| 2016-09-30 | $0.01B | $0.10B | 11.55% |
| 2016-06-30 | $0.01B | $0.10B | 10.90% |
| 2016-03-31 | $0.01B | $0.09B | 10.17% |
| 2015-12-31 | $0.01B | $0.09B | 9.38% |
| 2015-09-30 | $0.01B | $0.09B | 8.46% |
| 2015-06-30 | $0.01B | $0.08B | 7.32% |
| 2015-03-31 | $0.01B | $0.08B | 6.13% |
| 2014-12-31 | $0.00B | $0.08B | 5.08% |
| 2014-09-30 | $0.00B | $0.08B | 3.95% |
| 2014-06-30 | $0.00B | $0.08B | 4.18% |
| 2014-03-31 | $0.00B | $0.07B | 4.44% |
| 2013-12-31 | $0.00B | $0.07B | 6.06% |
| 2013-09-30 | $0.00B | $0.07B | 6.23% |
| 2013-06-30 | $0.00B | $0.06B | 6.37% |
| 2013-03-31 | $0.00B | $0.06B | 6.48% |
| 2012-12-31 | $0.00B | $0.06B | 4.94% |
| 2012-09-30 | $0.00B | $0.06B | 3.33% |
| 2012-06-30 | $0.00B | $0.06B | 3.31% |
| 2012-03-31 | $0.00B | $0.06B | 3.28% |
| 2011-12-31 | $0.00B | $0.06B | 3.25% |
| 2011-09-30 | $0.00B | $0.06B | 6.43% |
| 2011-06-30 | $0.01B | $0.06B | 8.10% |
| 2011-03-31 | $0.01B | $0.06B | 9.88% |
| 2010-12-31 | $0.01B | $0.06B | 11.72% |
| 2010-09-30 | $0.01B | $0.06B | 10.30% |
| 2010-06-30 | $0.01B | $0.06B | 8.77% |
| 2010-03-31 | $0.00B | $0.06B | 7.14% |
| 2009-12-31 | $0.00B | $0.06B | 1.83% |
| 2009-09-30 | $0.00B | $0.06B | 0.00% |
| 2009-06-30 | $-0.00B | $0.05B | -1.88% |
| 2009-03-31 | $-0.00B | $0.05B | -5.58% |
| 2008-12-31 | $-0.00B | $0.05B | -7.24% |
| 2008-09-30 | $-0.01B | $0.05B | -8.77% |
| 2008-06-30 | $-0.01B | $0.06B | -10.39% |
| 2008-03-31 | $-0.01B | $0.06B | -8.66% |
| 2007-12-31 | $-0.00B | $0.06B | -5.22% |
| 2007-09-30 | $-0.00B | $0.06B | -3.54% |
| 2007-06-30 | $-0.00B | $0.06B | -4.73% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.603B | $0.106B |
| LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.673B | 26.23 |
| Medtronic (MDT) | Ireland | $124.635B | 18.20 |
| Stryker (SYK) | United States | $69.927B | 25.67 |
| Boston Scientific (BSX) | United States | $55.591B | 27.10 |
| Baxter (BAX) | United States | $39.448B | 24.31 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.289B | 16.23 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.755B | 0.00 |
| ResMed (RMD) | United States | $14.297B | 27.11 |
| Canopy Growth (CGC) | Canada | $10.742B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.172B | 52.25 |
| Aurora Cannabis (ACB) | Canada | $7.060B | 50.50 |
| Hill-Rom Holdings (HRC) | United States | $6.958B | 21.52 |
| Perrigo (PRGO) | Ireland | $6.649B | 10.09 |
| ICU Medical (ICUI) | United States | $5.184B | 28.88 |
| Insulet (PODD) | United States | $5.071B | 0.00 |
| Haemonetics (HAE) | United States | $4.540B | 40.28 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.400B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.380B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.329B | 0.00 |
| Neogen (NEOG) | United States | $3.267B | 50.18 |
| NuVasive (NUVA) | United States | $2.850B | 24.96 |
| Quidel (QDEL) | United States | $2.761B | 24.91 |
| National Vision Holdings (EYE) | United States | $2.637B | 51.01 |
| Aphria (APHA) | $2.539B | 112.78 | |
| NxStage Medical (NXTM) | United States | $2.000B | 0.00 |
| AtriCure (ATRC) | United States | $1.274B | 0.00 |
| HEXO (HEXO) | $1.242B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.240B | 890.25 |
| Phibro Animal Health (PAHC) | United States | $1.220B | 17.53 |
| VAREX IMAGING (VREX) | United States | $1.212B | 23.73 |
| MacroGenics (MGNX) | United States | $0.939B | 0.00 |
| Cerus (CERS) | United States | $0.904B | 0.00 |
| PetIQ (PETQ) | United States | $0.867B | 22.47 |
| Lantheus Holdings (LNTH) | United States | $0.847B | 22.95 |
| Surmodics (SRDX) | United States | $0.785B | 114.20 |
| Meridian Bioscience (VIVO) | United States | $0.733B | 21.85 |
| NanoString Technologies (NSTG) | United States | $0.721B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.720B | 31.76 |
| Omeros (OMER) | United States | $0.719B | 0.00 |
| Evolus (EOLS) | United States | $0.705B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.647B | 20.75 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.426B | 0.00 |
| Owens & Minor (OMI) | United States | $0.408B | 5.65 |
| TG Therapeutics (TGTX) | United States | $0.398B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.339B | 21.99 |
| BioLife Solutions (BLFS) | United States | $0.329B | 445.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.294B | 0.00 |
| Vapotherm (VAPO) | United States | $0.288B | 0.00 |
| Bovie Medical (APYX) | United States | $0.282B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.262B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.256B | 0.00 |
| Zynex (ZYXI) | United States | $0.174B | 16.84 |
| Fonar (FONR) | United States | $0.144B | 7.70 |
| Surface Oncology (SURF) | United States | $0.140B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.112B | 0.00 |
| Chimerix (CMRX) | United States | $0.100B | 0.00 |
| United-Guardian (UG) | United States | $0.090B | 18.77 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.078B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 18.20 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.057B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 14.14 |
